In order to develop platinum complexes with selective activity in primary and secondary bone malignancies and with the aim to optimize antitumor activity, platinum(II) complexes with aminotris(methylenephosphonic acid) as bone-seeking (osteotropic) ligand have been synthesized, characterized and tested in the cisplatin-sensitive ovarian carcinoma cell line CH1. As non-leaving diamine ligands, which are decisive for the cellular processing of DNA adducts, cis-R,S-cyclohexane-l,2-diamine, trans-S,S-cyclohexane-l,2-diamine and trans-R,R-cyclohexane-l,2-diamine have been used, resulting in complexes I, 2, and 3, respectively. The cytotoxicity of the complexes under investigation decreases in the order 3 > 2 > which is in accord with structure-activity relationships with other (cyclohexane-l,2-diamine)platinum(II) and platinum(IV) complexes: Both trans complexes (2 and 3) display a higher in vitro potency than the corresponding cis isomer (I), with the trans-R,R isomer (3) being the most active in this series. In comparison to the analogous (cyclohexane-l,2-diamine)platinum(II) complexes with bis(phosphonomethyl)aminoacetic acid as osteotropic carrier ligand, the cytotoxicity of I-3 was found to be 1.5 2 fold higher, which is explainable by a different coordination mode of the phosphonic acid ligands (acetato versus phosphonato).
INTRODUCTION
Since the recognition of the cytotoxic activity of cisplatin (Figure 1 ) in the late 1960s/1,2,3,4/, thousands of platinum complexes have been synthesized in order to develop similar drugs with improved antitumor activity and with a better toxicological profile/5,6/. Carboplatin is the result of such attempts; it has, due to the same diammineplatinum(lI) moiety, equivalent efficacy but milder toxicity because of the 1,1-cyclobutanedicarboxylato leaving group. In the case of oxaliplatin, which has been approved in 1999 in Europe and in 2002 in the US, the substitution of the two ammine ligands with the cyclohexane-l,2-diamine (or DACH diaminocyclohexane) moiety led to the third platinum-based anticancer compound in worldwide clinical use with good antitumor properties and partial lack of cross-resistance with cisplatin/7,8/. Oxaliplatin (Eloxatin; Sanofi-Synthelabo), which has a more favorable safety profile than cisplatin, is indicated in combination with 5-fluorouracil (5-FU) and leucovorin for patients with colorectal cancer.
In order to synthesize platinum complexes with selective activity in primary and second.ary bone malignancies such as osteosarcoma (bone tumors) as well as in lethal ossifying lung metastases and bone metastases from tumors with other primary sites, a series of osteotropic (bone-seeking) [(bis(phosphonomethyl)amino-:N)acetato-:O(2-)]platinum(II) complexes has been synthesized/9,10,11/.
With the aim of exploring structure-activity relationships, different, kinds of diam(m)ine ligands, which are decisive for the cellular processing of DNA adducts, have been used (Figure 2 ) /12/. However, the bis(phosphonomethyl)-substitutcd amino acetic acid (BPMAA) ligand, which has a high affinity for calcium and calcified tissues and which is therefore responsible for the carrier-mediated transport to the mineral bone matrix, was left unchanged in this study. S,S-cyclohexane-1,2-diamine or trans-R,R-cyclohexane-l,2-diamine.
Within the series of complexes, the in vitro antitumor activity in the cisplatin-sensitive ovarian carcinoma cell line CH1 decreases depending on the coordinated diam(m)ine ligand in the following order (Table 1) : In order to set up structure-activity relationships and to optimize antitumor activity of osteotropic platinum-based complexes, we have focused on the synthesis of platinum(If) compounds with (cyclohexane-1,2-diamine) as non-leaving diamine ligand. As bone-seeking carrier ligand a tris(phosphonic acid), ATMP, aminotris(methylenephosphonic acid), was selected.
EXPERIMENTAL
The structure of the phosphonatoplatinum(II) complexes under investigation as well as the numbering scheme for the NMR study is illustrated in Figure 3 . We will refer to these compounds as complexes I, 2 and Platinum(ll) 3 in case of a cis-R,S-, trans-S,S-and trans-R,R-cyclohexane-l,2-diamine ligand, respectively. (SP-4-2)-Dichloro(cis-R,S-cyclohcxanc-l,2-diaminc)platinum(ll) (400 mg, 1.05 mmol) was suspended in 15 ml of water. After addition of silver nitrate (340 mg, 2.0 mmol), the mixture was stirred overnight at room temperature. Silver 
The synthetic procedure is the same as that for complex 1 
RESULTS AND DISCUSSION

Syntheses
Synthesis of the bis(phosphonomethyl)amino-KN)methylphosphonato-KO(2-)l(cyclohexane-1,2-diamine-K"N,N')platinum(ll) complexes I-3 was accomplished in three steps in analogy to the synthetic procedure of the bis(phosphonomethyl)-substituted aminoacetatoplatinum(lI) counterparts, as described previously /12/. The dichloro (cyclohexane-l,2-diamine) platinum(II) complexes are synthesized in one step, starting from K2PtC14 and the cis-R,S-, trans-S,S-and trans-R,R-cyclohexane-l,2-diamine ligands. After that, the dichloroplatinum(II) species are activated over night using silver nitrate (Scheme 1). After removing the precipitated silver chloride, aminotris(methylenephosphonic acid), ATMP, is added, and the bis(phosphonomethyl)amino-N)methylphosphonato-cO(2-)]platinum(II) complexes 1-3 are formed.
Purity of the compounds was checked by elemental analysis, whereas coordination of the ATMP ligand can best be judged by 31p NMR spectroscopy.
NMR spectroscopy
In phosphorus NMR, the free ligand resonates at 9.3 ppm, whereas in complexes 1-3 a significant downfield shift of the signals can be observed: In the region between 43.7 and 44.0 ppm, a 31p signal of the coordinated phosphonato residue is found; resonances of the uncoordinated phosphonomethyl groups are located between 12.7 and 13.4 ppm. In case of the (trans-cyclohexane-l,2-diamine)platinum(II) complexes 2 and 3, two signals can be detected with a separation of 0.6 ppm in the region around 13.0 ppm, reflecting the nonequivalcnce of the uncoordinated phosphonomethyl groups. This is in accordance with the analogous BPMAA complexes, where signals between 12.6 and 13.0 ppm could be found/12/. In the case of the cis-R,S-cyclohexane-l,2-diamine ligand, two isomers are formed with either NH2-(CR) or NH2-(Cs) in trans position to the coordinated phosphonato group. For this mixture, only one unresolved 3p chemical shift at 13 .3 ppm could be detected.
IH and 3C resonance assignment was performed by analysis of two-dimensional 1H,H and 3C,H shift correlated spectra, as will be demonstrated for complex 1 in the following section. Two kinds of isolated spin systems can be detected in the H,H-COSY NMR spectrum of complex ( Starting from these resonances, a vicinal coupling to the methine protons H(4) and H(5) at 2.66 and 2.91 ppm of the cyclohexane ring can be observed. H(4) and H(5) display a distinct cross peak to the neighboring CH2 groups H(6) and H(9) which merge to one unresolved multiplett at 1.66 ppm. Consequently, the resonances at 1.17, 1.31 and 1.57 ppm, which are found in a ratio of 1:2:1, originate from the methylene protons H(7) and H(8).
3C resonance assignment for complex was performed by analyzing LC,H connectivities in the twodimensional 3C,H-COSY NMR spectrum ( Figure 5 ). 1,2-diamine-K2N,N')platinum(ll) complexes 1-3 has been compared in the highly cisplatin-sensitive human ovarian cancer cell line CH1. Concentration-effect curves were obtained after exposure for 96 hours by means of a colorimetric microculture assay (MTT assay). The concentration-effect curves for I-3 are shown in Figure 6 , whereas the corresponding IC.s0 values are reported in Table 2 . As expected, the in vitro antitumor activity decreases depending on the stereochemistry of the cytotoxic (cyclohexane-l,2-diamine)platinum(II) moiety in the following order: 3 > 2 > I. Both trans complexes 3 and Table 2 Cytotoxic activity of [(bis(phosphonomethyl) 
